Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea.

Nicole E Scangarella-Oman,Mohammad Hossain,Caroline R Perry,Courtney Tiffany,Marcy Powell,Brandon Swift,Etienne F Dumont

Sexually transmitted infections（2023）

引用 10|浏览5

暂无评分

摘要

Two gepotidacin 3000 mg oral doses 10-12 hours apart provide ~2-fold higher systemic exposures, increase efficacy for higher gepotidacin MIC isolates, reduce resistance potential and limit plasma concentrations of potential safety concern, compared with higher doses.

查看译文

关键词

clinical trial,gonorrhoea,neisseria gonorrhoeae

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要